Table 3.
Equations to predict EQ-5D and OAB-5D utilities from symptom frequency level
| Effect |
EQ-5D utility |
OAB-5D utility |
||||
|---|---|---|---|---|---|---|
| β estimate | β SE a | P value b | β estimate | β SE a | P value b | |
| Intercept |
0.940 |
0.0230 |
<.0001 |
0.766 |
0.0085 |
<.0001 |
| Age |
-0.001 |
0.0002 |
0.0006 |
0.0003 |
0.0001 |
<.0001 |
| Gender: female vs. male |
-0.021 |
0.0063 |
0.0006 |
0.005 |
0.0024 |
0.0551 |
| BMI |
-0.003 |
0.0004 |
<.0001 |
-0.001 |
0.0002 |
0.0003 |
| Previously treated with antimuscarinics |
-0.019 |
0.0055 |
0.0006 |
-0.017 |
0.0021 |
<.0001 |
| Micturitions level: 1 vs. 5 |
0.056 |
0.0057 |
<.0001 |
0.088 |
0.0022 |
<.0001 |
| Micturitions level: 2 vs. 5 |
0.040 |
0.0052 |
<.0001 |
0.055 |
0.0021 |
<.0001 |
| Micturitions level: 3 vs. 5 |
0.029 |
0.0051 |
<.0001 |
0.035 |
0.0020 |
<.0001 |
| Micturitions level: 4 vs. 5 |
0.019 |
0.0051 |
0.0002 |
0.019 |
0.0020 |
<.0001 |
| Incontinence episodes level: 1 vs. 5 |
0.052 |
0.0052 |
<.0001 |
0.076 |
0.0020 |
<.0001 |
| Incontinence episodes level: 2 vs. 5 |
0.037 |
0.0052 |
<.0001 |
0.048 |
0.0020 |
<.0001 |
| Incontinence episodes level: 3 vs. 5 |
0.022 |
0.0054 |
<.0001 |
0.025 |
0.0021 |
<.0001 |
| Incontinence episodes level: 4 vs. 5 |
0.011 |
0.0058 |
0.0481 |
0.012 |
0.0023 |
<.0001 |
| Study: SCORPIO vs. CAPRICORN |
-0.019 |
0.0081 |
0.0174 |
-0.012 |
0.0030 |
<.0001 |
| Study: ARIES vs. CAPRICORN | -0.008 | 0.0083 | 0.3409 | 0.004 | 0.0031 | 0.1984 |
aSE: Standard error.
bt-test to test the null hypothesis that the associated β estimate equals zero.